Biotech News
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
Label Expansion and Global Progress FDA Expanded Approval: On October 14, 2026, the U.S. Food and Drug Administration ( FDA) approved our supplemental Biologics License Application (sBLA) expanding the approved indication for ANKTIVA ® in combination with Bacillus Calmette-Guérin (BCG) to include
